Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers
US8409580B2 · kind B2 · utility
2Cited by
10References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 30, 2010 |
| Grant date | Apr 2, 2013 |
| Priority date | — |
| Expiry date | Jan 13, 2031 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/6018
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to an immunogenic composition which comprises, firstly, a carrier and, secondly, as antigenic structure, conjugates comprising all or part of the amino acid sequences of at least one peptide derived from an extracellular loop of the P-170 protein, each peptide being combined with several molecules of fatty acid containing a carbon chain of between C12 and C24 so as to allow, under suitable administration conditions, the induction of anti-P-170 antibodies.The invention relates to said composition for defining means for treating multidrug resistances.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.